Sanofi and GlaxoSmithKline plc- Notable Market Players in Travel Vaccine Market
Travel vaccines, also called travel immunizations, are shots travelers get before visiting certain areas of the world that help protect them from developing serious illnesses. Vaccinations work by exposing the body to a weakened/dead germ or part of a germ of the disease. These vaccines are recommended to provide protection against diseases endemic to the country of origin or of the destination. It is intended to protect travelers and to prevent disease spread within or between countries. In many cases, countries require proof of vaccination for travelers wishing to enter or exit the country.
Market leaders operating in the market have undertaken various organic growth strategies in the travel vaccine market. The Travel Vaccine market majorly consists of the players including GlaxoSmithKline plc.; Merck & Co., Inc.; Sanofi; Novartis AG; Pfizer Inc.; Dynavax Technologies; Emergent BioSolutions Inc.; Abbott; Seqirus; and Valneva SE among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.
Below is the list of the growth strategies done by the players operating in the travel vaccine market:
| Company | Month & Year | Category | Description |
| Emergent BioSolutions Inc | Dec-2021 | Product News | Emergent BioSolutions Inc. announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate. The current version of the influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses. |
| Seqirus | Jun-2021 | Company News | First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool. Seqirus Liverpool produce over 50m doses of seasonal influenza vaccine each year, with the ability to increase production to 200m doses in the event of an influenza pandemic. |
| Sanofi | Mar-2021 | Expansion | Sanofi made an investment of more than €600 million in a new vaccine manufacturing facility at its existing site in Toronto, Canada. The investment in a new facility provided additional antigen and filling capacity for Sanofi’s Fluzone High-Dose Quadrivalent influenza vaccine, helping to increase supply availability in Canada, the United States and Europe. |
| Dynavax Technologies Corporation | Jan-2021 | Product News | Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing vaccines, announced final immunogenicity and interim safety results of the ongoing clinical trial evaluating HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in patients undergoing hemodialysis. |
| Sanofi | Jun-2020 | Expansion | Sanofi made significant investments in France to increase its vaccines research and production capacities and contribute to responding to future pandemic risks. Aligned with its corporate strategy presented in December, Sanofi invests €610 million to create a new production site and research center in France with both dedicated to vaccines. |
| Sanofi | Apr-2020 | Product Approval | Sanofi has received approval from the U.S. Food and Drug Administration (FDA) for a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine for the prevention of invasive meningococcal disease. |
| Abbott | Feb-2020 | Product Launch | Abbott introduced a new inactivated quadrivalent vaccine for influenza. The new vaccine is the first of its kind sub-unit vaccine delivering protection against four virus strains, in India. It is the only 0.5 ml quadrivalent flu vaccine in India that has been approved for usage in children below 3 years. |
| Sanofi | Nov-2019 | Product Approval | Sanofi’s Fluzone supplemental Biologics License Application was approved by the U.S. Food and Drug Administration (FDA) for use in adults 65 years of age and older. Fluzone High-Dose (Influenza Vaccine) was approved by the FDA in 2009 as a trivalent influenza vaccine, including two influenza A strains and one influenza B strain. It help prevent influenza disease caused by influenza A and B strains contained in the vaccine. |
| Sanofi | Dec-2018 | Product Approval | Sanofi Vaccine VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate Meningococcal Protein Conjugate and Hepatitis B Recombinant Vaccine) was approved by the U.S. Food and Drug Administration for use in children from 6 weeks through 4 years of age. VAXELIS was developed as part of a joint-partnership between Sanofi and MSD. |
| Pfizer Inc. | Apr-2018 | Product News | Pfizer Inc. TRUMENBA (Meningococcal Group B Vaccine) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB) in children ages 1 through 9 years. TRUMENBA previously received Breakthrough Therapy designation in 2014 for the prevention of MenB in adolescents and young adults ages 10 through 25 years. |
| GlaxoSmithKline plc | Feb-2018 | Product Approval | GlaxoSmithKline plc received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its meningitis B vaccine Bexsero [Meningococcal group B Vaccine (rDNA, component, adsorbed)] for the development of the vaccine in the prevention of Invasive Meningococcal Disease (IMD) caused by serogroup B in children 2-10 years of age. |
| Seqirus | Jul-2022 | Collaboration | Seqirus has entered a multi-year influenza research partnership with the University of Liverpool Pandemic Institute. Under the partnership, Seqirus will participate in research projects and knowledge generation around both the threat of seasonal influenza and the development of innovative approaches to pandemic preparedness and response. |
| GlaxoSmithKline plc | Dec-2021 | Joint Venture | GlaxoSmithKline (GSK) plc welcomed the decision of the Gavi Board to provide funding for the procurement and introduction of malaria vaccines into routine child immunisation programmes in Gavi eligible countries. The announcement followed shortly after WHO recommendation for the broader use of GSK’s RTS,S/AS01e to reduce childhood illness and deaths from malaria in children living in sub-Saharan Africa and other regions. |
| Dynavax Technologies Corporation | May-2021 | Collaboration | Dynavax Technologies Corporation entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany. |
| GlaxoSmithKline plc | Mar-2021 | Joint Venture | GSK entered into an agreement to supply its rotavirus vaccine, Rotarix, through the Humanitarian Mechanism for civil society organizations. The vaccine was made available at lowest global price for the tube presentation. The agreement builds on GSK’s existing commitment to the Humanitarian Mechanism for its PCV (pneumococcal conjugate vaccine), Synflorix, at the lowest global price for its four-dose vial presentation, also supplied to UNICEF. |
| GlaxoSmithKline plc | Feb-2021 | Collaboration | GlaxoSmithKline plc and Vir Biotechnology, Inc. had signed a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses. |
| Merck & Co., Inc. | Jun-2020 | Mergers and Acquisitions | Merck acquired Themis, a privately-held company emphasized on immune-modulation therapies and vaccines for infectious diseases and cancer. As a result of the acquisition, Themis will operate as a wholly-owned subsidiary of Merck. |
| Sanofi | Jun-2020 | Collaboration | Sanofi Pasteur and Translate Bio have expanded their existing 2018 collaboration and license agreement to develop mRNA vaccines for infectious diseases. |
| Valneva SE | Jun-2020 | Partnership | Valneva SE and Bavarian Nordic A/S signed a binding term sheet to establish a partnership for the marketing and distribution of their commercial products. The partnership provided both companies with additional critical mass, significant commercial synergies, and a market leadership position in the specialty vaccine industry. |
| GlaxoSmithKline plc | Dec-2019 | Mergers and Acquisitions | GlaxoSmithKline plc completed the divestment of travel vaccines Rabipur for the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic. GSK received an upfront payment of USD 348 million. |
| Merck & Co., Inc. | Oct-2019 | Partnership | Merck partnered with 4D Pharma, to develop Live Biotherapeutics vaccines. Under the terms of the deal, 4D use sits proprietary MicroRx platform with Merck’s expertise in novel vaccine development and commercialization to discover and develop Live Biotherapeutics (LBPs) as vaccines in up to three currently undisclosed indications. |
| GlaxoSmithKline plc | Oct-2019 | Mergers and Acquisitions | GlaxoSmithKline plc had agreed to divest travel vaccines Rabipur to prevent rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic. The decision to divest these brands, acquired from Novartis in 2015, supports GSK’s strategic intent to increase focus and reinvest in growth assets, innovation, and a simplified supply chain in its vaccines business. |
| GlaxoSmithKline plc | Jun-2018 | Mergers and Acquisitions | GlaxoSmithKline plc acquired about 36.5% stake in its Consumer Healthcare from Novartis for an estimated value of about US$13 billion. This acquisition helped the company to strengthen its Consumer Healthcare business worldwide. |
